Table 2

proptosis measurements for patients

Study phaseCaseBaseline
study eye
Week 24
study eye
Baseline
fellow eye
Week 24
fellow eye
Baseline
asymmetry
Week 24
asymmetry
A: Teprotumumab group
 312828242444
 322119181831
 332020171832
 342526222333
 352121171843
 362423.5192054
 272421211932
 281616.5121641
 291921161734
 2102830252535
 2112525222332
 2122223181746
 Mean22.822.819.319.83.53.1
 SD3.63.93.73.10.71.6
B: Placebo group
 312828242444
 322119181831
 332020171832
 342526222333
 352121171843
 362423.5192054
 272421211932
 281616.5121641
 291921161734
 2102830252535
 2112525222332
 2122223181746
 Mean22.822.819.319.83.53.1
 SD3.63.93.73.10.71.6